Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with Research Unit for Psychotherapy and Psychopathology, Psychiatry West, Slagelse, Region Zealand Mental Health Services, who will use Monsenso’s digital health solution to remotely monitor patients with depression and schizotypal mental illness, respectively.

The first project, Development of an Intervention for Persistent Not on Track: DIP NOT, led by Jasmin Rejaye Gryesten, aims to identify non-responders to depression treatment, with the ultimate goal of increasing the number of remitted patients after CBT in the Danish MHS by developing a set of new person-centered add-on interventions to group CBT, to be used in case of observed lack of progress or deterioration.

The second project Phenomenologically informed PsychoTherapy for patients with Schizotypal Personality Disorder (PPT -SPD), is led by Kåre Donskov Nielsen and aims to develop and test new forms of phenomenological therapy that can help people with schizotypal mental illness.

About Monsenso digital health solution:
The Monsenso solution is a clinically validated, CE Class I Marked mHealth solution classified as a Medical Device, consisting of a smartphone app for patients and a clinical web portal for healthcare providers that are widely used in the prevention and treatment of common behavioural disorders such as depression and anxiety. It can also be configured to prevent and treat severe mental illnesses such as depression, bipolar disorder, borderline personality disorder, PTSD, and schizophrenia. It is currently being used by over 1,000 patients across the globe and is highly valued by patients and healthcare providers.

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Mental health affects all aspects of our life. ​Yet, it’s the most neglected area

Mental health affects all aspects of our life. ​Yet, it’s the most neglected area

Mental health affects all aspects of our life. ​Yet, it’s the most neglected area of public health, driving higher risk of comorbid disorders and mortality. 

​’Mental health’ as a term refers to cognitive, behavioral, and emotional well-being. It is all about how we think, feel, and behave. The state of your mental health determines how you handle stress, how you relate to others, and how you make healthy choices. As such, mental health affects all aspects of daily living, relationships, and physical health. For some people, “mental health” means the absence of a mental disorder. For others, it equals a life with daily stressors, mood disorders, affecting their ability to function.

Close to 1 billion people globally are living with a mental disorder[1]. In fact, mental disorder affects one in four families – a number which is expected to rise significantly over the next 20 years [2]. As measured by ’years of life lived with disability’, mental illness is the biggest disease burden in society today[3].

Without doubt, mental health is an important topic. Yet, the magnitude and burden of mental disorders remain unmet by the response. Countries across the globe have long overlooked the issue of mental health and mental illness. As such, more than 33% of countries allocate less than 1% of the total health budgets to mental health, with another 33% of countries spending just 1% of their budgets on mental health[4]. Consequently, relatively few people around the world have access to quality mental health services. In low- and middle-income countries, more than 75% of people with mental, neurological and substance use disorders receive no treatment for their condition at all [5].

If left untreated, mental illness can lead to other commodity disorders, such as depression, substance abuse and even early mortality. Substance abuse is common among people who are battling a depressive disorder, which can lead to further exacerbation of the symptoms related to depression, impairing mental functioning, and further damaging overall spirit, quality of life. Likewise, many individuals who develop substance use disorders (SUD) are also diagnosed with mental disorders, and vice versa. As such, mental health disorder patients accounts of 44% of cocaine and 38% of alcohol consumption​ [6,7]. ​

The magnitude, suffering and burden in terms of disability and costs for individuals, families and societies are staggering. Every year, the harmful use of alcohol results in millions of deaths, including hundreds of thousands of young lives lost. Illicit drug use disorders is – directly and indirectly – responsible for over 750,000 deaths per year. ​Not to mention, the 1 million people, whom commit suicide every year across the world [8].

Mental health has been hidden behind a curtain of stigma and discrimination for too long. It is time to bring it out into the open. Help us raise awareness, by sharing our post.

To learn more about how Monsenso mhealth solution can be used to increase treatment outcome, see our video below:

-> BOOK A DEMO

Sources:

[1]WHO -2020

[2] WHO -2001

[3] WHO – 2012

[4] WHO – 2019 

[5] WHO – The Mental health Gab Action Programme (mhGAP)

[6] Drugabuse.org, The national Bureau of Economic research – 2020

[7] The National bureau of economic research. Mental health and substance abuse. 2020.

[8] WHO – Investigating in mental health

New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster. Monsenso enters a partnership with Empano, a private player in psychology and psychiatry services. Together, Monsenso and Empano offer a solution for the Danish municipalities to support unemployed people suffering with stress and depression in their return to work process. Initially, the solution will be implemented in Guldborgssund Municipality, Denmark, in September 2020.

“In a situation with historically high unemployment, we are pleased to offer a solution that can help get more Danes back into the labor force faster. It’s always difficult to be outside the labor force, and even more so if you suffer from stress and depression. “Therefore, we are pleased to offer a solution to municipalities that can help unemployed people suffering with stress and depression get back to work” says CEO Thomas Lethenborg.

“The municipalities are facing a major task due to the increased unemployment we are seeing in the wake of Covid-19. The combination of our services in the psychology and psychiatry services, and Monsenso’s platform to support follow-up and data collection is unique in the market and we are convinced that the service can help municipalities to proactively help the larger group of unemployed ” says Director Camilla Stokholm Bjørkman from Empano. 

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs agreement to support global pharmaceutical across Europe

Monsenso signs agreement to support global pharmaceutical across Europe

Following a year-long collaboration, Monsenso signs a three-year +10 mio DKK agreement with a global pharmaceutical company.

Monsenso’s mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France.

In connection with the two studies, Monsenso’s solution will be used to collect data from patients and their relatives through clinical questionnaires, daily self-assessments and behavioral data from smartphones and wearables.

In addition, the patients will be offered in-app study information and can receive reminders about medication and consultations with their clinician. Monsenso’s unique mobile health solution will in this way help increase the quality of clinical studies with real-time data collection while also facilitating better communication between patients, caregivers and clinicians.

“We are very pleased to expand our collaboration with this global pharmaceutical company and to participate in these projects. Depression is a leading burden of disease for society, and it has severe consequences for patients and their family caregivers, so we are proud to contribute to solving this problem” says Thomas Lethenborg, CEO of Monsenso. “In addition, the project will support our European expansion and our focus on partnering with pharmaceuticals, which is in line with our strategy”. 

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso